319 related articles for article (PubMed ID: 29233294)
1. The Keap1-Nrf2 protein-protein interaction: A suitable target for small molecules.
Schmoll D; Engel CK; Glombik H
Drug Discov Today Technol; 2017 Jun; 24():11-17. PubMed ID: 29233294
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
3. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances of Natural Polyphenols Activators for Keap1-Nrf2 Signaling Pathway.
Zhou Y; Jiang Z; Lu H; Xu Z; Tong R; Shi J; Jia G
Chem Biodivers; 2019 Nov; 16(11):e1900400. PubMed ID: 31482617
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
6. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
7. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
[TBL] [Abstract][Full Text] [Related]
8. Thermodynamic profiling of inhibitors of Nrf2:Keap1 interactions.
Nasiri HR; Linge S; Ullmann D
Bioorg Med Chem Lett; 2016 Jan; 26(2):526-529. PubMed ID: 26653613
[TBL] [Abstract][Full Text] [Related]
9. A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
Tran KT; Pallesen JS; Solbak SMØ; Narayanan D; Baig A; Zang J; Aguayo-Orozco A; Carmona RMC; Garcia AD; Bach A
J Med Chem; 2019 Sep; 62(17):8028-8052. PubMed ID: 31411465
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
11. Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery.
Madden SK; Itzhaki LS
Biochim Biophys Acta Proteins Proteom; 2020 Jul; 1868(7):140405. PubMed ID: 32120017
[TBL] [Abstract][Full Text] [Related]
12. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
13. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
[TBL] [Abstract][Full Text] [Related]
15. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
[TBL] [Abstract][Full Text] [Related]
16. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.
Qin JJ; Cheng XD; Zhang J; Zhang WD
Cell Commun Signal; 2019 Sep; 17(1):121. PubMed ID: 31511020
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
Lu MC; Shao HL; Liu T; You QD; Jiang ZY
Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
[TBL] [Abstract][Full Text] [Related]
18. Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interaction.
Steel RJ; O'Connell MA; Searcey M
Bioorg Med Chem Lett; 2018 Sep; 28(16):2728-2731. PubMed ID: 29534931
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanism.
Horie Y; Suzuki T; Inoue J; Iso T; Wells G; Moore TW; Mizushima T; Dinkova-Kostova AT; Kasai T; Kamei T; Koshiba S; Yamamoto M
Commun Biol; 2021 May; 4(1):576. PubMed ID: 33990683
[TBL] [Abstract][Full Text] [Related]
20. ZJ01, a Small Molecule Inhibitor of the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction, Reduces Hyperoxic Acute Lung Injury in a Mouse Model.
Wan J; Lin S; Huang X; Li Q; Zeng L; Du S
Med Sci Monit; 2020 May; 26():e920467. PubMed ID: 32437336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]